Proactive Investors - Run By Investors For Investors

Paradigm Biopharmaceuticals secures $61.3 million in first stage of raising

The capital raising has attracted a number of international institutional investors.
glass full of coins with plant growing out of it
The final stage of the raising being the retail rights issue will commence next week

Paradigm Biopharmaceuticals Ltd (ASX:PAR) has secured $61.3 million in funding from the institutional component of its rights issue and placement priced at $1.50.

An additional $16.6 million is expected to be raised through the retail component of the rights issue, which will open next Wednesday 24 April 2019.

This will take the total capital raising to $77.9 million as outlined earlier to the market on Monday.

READ: Paradigm Biopharmaceuticals raising $77.9 million to fund its pivotal phase 3 OA trial

Paradigm’s managing director Paul Rennie said: “On behalf of the board we delighted with the overwhelmingly positive response to the release of the osteoarthritis phase 2B secondary endpoint data (on 15 April) and this capital raise.

“The board believes that Paradigm has now secured funding for purposes including the conclusion of our pivotal phase 3 clinical trials for OA and MPS.

New international investors on board

“I take this opportunity to welcome new institutions from the UK, USA, Asia and Australia to the register and to thank our existing shareholders for their ongoing support.

“From a clinical perspective I note the significance of the indicative regression of disease demonstrated by our secondary endpoint data.

“With this combination of funding and compelling clinical data the company is well placed to progress its clinical program whilst pursuing potential commercial transactions.”

READ: Paradigm Biopharmaceuticals phase 2b trial achieves key endpoints in OA of the knee

On Monday this week, the company also revealed that it had successfully achieved the secondary endpoints of improved knee function and pain reduction for its phase 2b trial in OA of the knee.

View full PAR profile View Profile

Paradigm Biopharmaceuticals Ltd Timeline

Related Articles

cancerous cells
April 15 2019
The company’s cancer treatment is based on work undertaken by John Beard, a professor of embryology at Edinburgh University nearly 100 years ago
human kidneys
May 06 2019
The Danish company is seeking FDA approval of the test for use in both adults and children
lab worker
May 20 2019
Here we take a closer look at Scancell, which is at the vanguard of immuno-oncology
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use